Kang Soo Im, Shin Jae Hong, Wu Benjamin M, Choi Hak Soo
Institute for Cancer Genetics, Columbia University Irving Medical Research Center, 1130 St. Nicholas Ave, New York, NY 10032, USA.
Qunova Computing Inc., Chrono Building Suite 501, 316 Gajeongro, Daejeon 34130, Republic of Korea.
Int J Mol Sci. 2025 Nov 26;26(23):11443. doi: 10.3390/ijms262311443.
Multi-target drug design represents a paradigm shift in tackling the complexity and heterogeneity of diseases such as cancer. Conventional single-target therapies frequently face limitations due to network redundancy, pathway compensation, and adaptive resistance mechanisms. In contrast, deep generative models, empowered by advanced artificial intelligence algorithms, provide scalable and versatile platforms for the generation and optimization of small molecules with activity across multiple therapeutic targets. This review provides a comprehensive overview of the recent landscape of AI-driven deep generative modeling for multi-target drug discovery, highlighting breakthroughs in model architectures, molecular representations, and goal-directed optimization strategies. We also examine the emergence of self-improving learning systems, closed-loop frameworks that iteratively refine molecular candidates through integrated feedback, as a transformative approach to adaptive drug design. Finally, key challenges, current limitations, and emerging trends are discussed to guide the evolution of next-generation intelligent and autonomous drug discovery pipelines for multi-target therapeutics.
多靶点药物设计代表了应对癌症等疾病的复杂性和异质性方面的范式转变。传统的单靶点疗法由于网络冗余、通路补偿和适应性耐药机制,常常面临局限性。相比之下,由先进人工智能算法赋能的深度生成模型,为生成和优化具有跨多个治疗靶点活性的小分子提供了可扩展且通用的平台。本综述全面概述了用于多靶点药物发现的人工智能驱动深度生成建模的最新进展,重点介绍了模型架构、分子表示和目标导向优化策略方面的突破。我们还研究了自我改进学习系统的出现,即通过集成反馈迭代优化分子候选物的闭环框架,作为适应性药物设计的变革性方法。最后,讨论了关键挑战、当前局限性和新兴趋势,以指导用于多靶点治疗的下一代智能自主药物发现流程的发展。